Thymosin Alpha-1 (Thymalfasin), Research Reference

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide derived from prothymosin alpha, a protein naturally produced by thymic epithelial cells. It is also known as Thymalfasin and is marketed commercially under the brand name Zadaxin by SciClone Pharmaceuticals. Research has investigated Tα1 extensively for its immunomodulatory properties, and it has received regulatory approval in approximately 35 countries, primarily for chronic viral hepatitis.

Quick Reference

Overview

Thymosin Alpha-1 is an endogenous immunomodulatory peptide produced by thymic epithelial cells and secreted into circulation. Its primary characterised functions involve the differentiation and maturation of T-lymphocytes, the activation of natural killer (NK) cells, and the regulation of cytokine production.

Research has investigated Tα1 for its potential role in:

• Enhancing T-cell differentiation and maturation from thymic precursors
• Promoting NK cell cytotoxicity against virally infected and tumour cells
• Stimulating dendritic cell maturation and antigen presentation
• Increasing interferon-gamma production and modulating the Th1/Th2 cytokine balance
• Activating innate immune signalling via Toll-like receptor 9 (TLR9)

Clinical investigations have been conducted in several therapeutic areas, including chronic hepatitis B, chronic hepatitis C, post-chemotherapy immune recovery, sepsis-associated immunosuppression, cancer adjuvant therapy, and, more recently, COVID-19. Multiple clinical trials examining Tα1 in COVID-19 patients were conducted in China between 2020 and 2022.

Thymosin Alpha-1 is approved by regulatory authorities in approximately 35 countries. It is not approved by the United States Food and Drug Administration (FDA) and is classified as a research chemical in the United States.

Reported Protocols

The following information represents commonly reported research ranges drawn from anecdotal accounts and available research literature. These are not medical recommendations.

Subcutaneous Protocol

Subcutaneous injection is the only commonly reported administration route for Thymosin Alpha-1. Commonly reported doses range from 1.6 mg, administered twice weekly. This dose originates directly from the clinical trial protocols used in hepatitis B and hepatitis C research, where 1.6 mg subcutaneous twice weekly was the standard regimen studied over periods of 6 to 12 months.

• Dosing frequency: Twice weekly, with doses spaced approximately 3 to 4 days apart
• Cycle duration: Anecdotal research accounts describe cycles ranging from 4 weeks to 6 months depending on the intended application
• Loading phase: Unlike some peptides, a formal loading phase is not commonly described for Tα1 in the research literature; the standard twice-weekly schedule is applied from the outset

Immune Recovery and Adjuvant Contexts

In post-chemotherapy and oncology-adjacent research contexts, anecdotal accounts describe use at the same 1.6 mg twice-weekly dose, continued for the duration of the recovery period. Some accounts describe continuation for 4 to 8 weeks following the conclusion of a chemotherapy cycle.

Injection Site Selection

Subcutaneous injection is typically performed in the abdominal region, rotating sites with each injection. The thigh is reported as an alternative site. Rotation between sites is described in most anecdotal accounts to minimise localised tissue response.

Reported Effects

The following effects have been reported in preclinical research, clinical trials, and anecdotal accounts. This list reflects the research landscape and does not constitute confirmed clinical outcomes for any specific individual.

T-Lymphocyte and NK Cell Activity

Research has most consistently characterised Thymosin Alpha-1 for effects on:

• Enhancement of T-lymphocyte activity, particularly CD4+ helper T-cells and CD8+ cytotoxic T-cells
• Improved NK cell function and cytotoxic capacity against virally infected cells
• Restoration of immune function in individuals with documented immunodeficiency or immunosuppression following illness or treatment

In hepatitis B research, Tα1 administration was associated with increased viral clearance and improved seroconversion rates in some trials, an outcome attributed to its T-cell stimulating activity.

Vaccine Response Enhancement

Research has investigated Thymosin Alpha-1 as an adjuvant to improve vaccine responsiveness. Studies in elderly populations, who typically show reduced vaccine efficacy due to immunosenescence, have reported improved antibody titres following vaccination when Tα1 was administered concurrently. Research has also investigated its use alongside influenza and hepatitis B vaccines in immunocompromised individuals.

COVID-19 Research Context

Multiple clinical trials conducted in China between 2020 and 2022 investigated Thymosin Alpha-1 in the context of COVID-19, with researchers focusing on its potential to restore immune function in patients experiencing severe disease. Research has investigated Tα1 for potential effects on the dysregulated immune response associated with severe SARS-CoV-2 infection, including the reduction of inflammatory cytokine activity in certain patient subgroups. Results from these trials varied and continued to be analysed in the published literature through 2022 and beyond.

Sepsis and Critical Illness

Anecdotal reports and research literature have described investigation of Tα1 in sepsis-associated immunoparalysis, a condition in which systemic infection leads to profound immune suppression. Clinical research in this area has reported improved immune markers and, in some studies, improved mortality outcomes in treated patient subgroups, though results across trials have not been uniformly consistent.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following. This list does not constitute a comprehensive safety profile and should not be interpreted as predictive of individual outcomes.

Thymosin Alpha-1 is generally described as well-tolerated across the clinical trial literature. The hepatitis B and C trials, which represent the most extensive human safety dataset, reported adverse event profiles comparable to placebo in most studies, with the most common observations being mild and transient injection site reactions.

The compound is not reported to produce hormonal suppression, organ toxicity at studied doses, or the theoretical angiogenic concerns associated with Thymosin Beta-4 peptides, given its distinct mechanism of action.

Storage & Handling

Lyophilized Powder (Unreconstituted)

• Refrigerator (2-8°C): Preferred storage condition; commonly reported stable for 12 months or more when stored properly
• Room temperature: Some preparations are described as stable at room temperature for limited durations, but refrigeration is consistently recommended to preserve activity
• Freezer: Acceptable for long-term storage of the dry powder; avoid repeated freeze-thaw cycles
• Light sensitivity: Store in an opaque or amber vial away from direct light exposure

Reconstituted Solution

• Refrigerator (2-8°C): Thymosin Alpha-1 is notably more fragile than many other research peptides once reconstituted; use within 24 hours of reconstitution is the most commonly reported guideline
• Do not freeze a reconstituted solution; freezing degrades the peptide structure
• Sterile water is commonly reported as the diluent of choice for single-use vials; bacteriostatic water may be used for multi-use vials where multiple doses will be drawn over a short period, though the 24-hour guideline applies regardless
• Discard if the solution becomes cloudy, discoloured, or shows particulate matter

Reconstitution

Add the chosen diluent slowly to the lyophilized vial, directing the liquid along the inside wall rather than directly onto the peptide powder. Swirl gently; do not shake. Allow several minutes for complete dissolution. The 24-hour stability window begins at the point of reconstitution. See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

What is the difference between Thymosin Alpha-1 and TB-500? Thymosin Alpha-1 (Tα1) and TB-500 are both derived from the thymosin family of proteins but serve distinct biological roles. Thymosin Alpha-1 is derived from prothymosin alpha and is primarily investigated for immune modulation, T-cell differentiation, and antiviral applications. TB-500 corresponds to the actin-binding domain of Thymosin Beta-4 and is investigated primarily for tissue repair, wound healing, and angiogenesis. The two peptides act through different receptors and signalling pathways.

Why is Thymosin Alpha-1 dosed twice weekly rather than daily? The twice-weekly schedule originates from clinical research trials conducted for hepatitis B and C treatment, where 1.6 mg subcutaneous twice weekly was the protocol used. Pharmacokinetic data indicate that while plasma half-life is approximately 2 hours, the downstream immune stimulation persists beyond the peptide’s clearance. Anecdotal research accounts report that twice-weekly dosing maintains consistent T-cell activity without observable tachyphylaxis over the cycle duration.

What is the regulatory status of Thymosin Alpha-1? Thymosin Alpha-1, marketed under the brand name Zadaxin (SciClone Pharmaceuticals), has received regulatory approval in approximately 35 countries for treatment of chronic hepatitis B and C and as an immune adjuvant. It is not approved by the United States Food and Drug Administration (FDA) and is classified as a research chemical in the United States. Regulatory status varies by country; individuals should verify local regulations before acquisition or use.

Can Thymosin Alpha-1 be combined with other immune-focused peptides? Anecdotal research accounts describe Thymosin Alpha-1 being used alongside other immune-modulating compounds. It is sometimes discussed in combination with BPC-157, which has reported anti-inflammatory properties, or with peptides investigated for their effects on innate immunity. No controlled human trials have evaluated these combinations. Each compound is typically used at its individually reported dose when combined, and the interactions between them have not been systematically characterised.

Related Pages

Goals: Immune Support

Class: Thymosin Peptides

Comparisons: Thymosin Alpha-1 vs LL-37

Also see: TB-500 (a different thymosin family member, investigated for tissue repair rather than immune modulation)

References & Further Reading

• Garaci E. (2007). Thymosin alpha1: a historical overview. Annals of the New York Academy of Sciences, 1112, 14–20. PubMed →
• Goldstein AL, Garaci E (Eds.). (2007). Combination Therapies Including Thymosin Alpha 1 for the Treatment of Cancer and Other Diseases. Annals of the New York Academy of Sciences, 1112. PubMed →
• Andreone P, et al. (1996). Thymosin-alpha1 combined with lamivudine for hepatitis B patients with decompensated cirrhosis: a randomized controlled pilot trial. Journal of Hepatology. PubMed →
• Gao Y, et al. (2022). Thymosin Alpha-1 as an immunomodulatory agent in COVID-19: a clinical review. Frontiers in Immunology, 13. PubMed →
• Pei F, et al. (2020). Thymosin alpha 1 in treatment of patients with COVID-19 and immunodeficiency. Journal of Infection, 81(6), 975–978. PubMed →
• Tuthill CW, Rios I, McBeath R. (2007). Thymosin alpha 1: past clinical experience and future promise. Annals of the New York Academy of Sciences, 1112, 326–337. PubMed →